(Q43436136)

English

Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences (CICG) Geneva, Switzerland, 7 t

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conférences (CICG) Geneva, Switzerland, 7 t (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

World Health Organization

0 references

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

Marietjie Venter

13

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

object named as

Sue Huang

6

0 references

3

object named as

Nancy J Cox

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

10

object named as

Malik Peiris

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

William K Ampofo

1

object named as

William K Ampofo

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

16

object named as

Wenqing Zhang

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

17

object named as

Thedi Ziegler

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Geethani Wickramasinghe

15

object named as

Geethani Wickramasinghe

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Suleiman Al Busaidy

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Maria Giovanni

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Alan Hay

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Stephen Inglis

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Jackie Katz

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Talat Mokhtari-Azad

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Vilma Savy

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Pathom Sawanpanyalert

12

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Anthony L Waddell

14

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

WHO Writing Group

18

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

language of work or name

0 references

publication date

17 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

3209-3221

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Real-time monitoring of the influenza vaccine field effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Airborne transmission of influenza A/H5N1 virus between ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Reproducibility of serologic assays for influenza virus A (H5N1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Mapping the antigenic and genetic evolution of influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 201

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

A metagenomic analysis of pandemic influenza A (2009 H1N1) infection in patients from North America

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Mixed infection and the genesis of influenza virus diversity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Rapid estimation of binding activity of influenza virus hemagglutinin to human and avian receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Mapping of H3N2 influenza antigenic evolution in China reveals a strategy for vaccine strain recommendation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Temporally structured metapopulation dynamics and persistence of influenza A H3N2 virus in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Network analysis of global influenza spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

The global circulation of seasonal influenza A (H3N2) viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.05.049

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.05.049

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43436136&oldid=2119238629"